ImmuPharma Files International Patent Application for P140 Immunormalizer

MT Newswires · 2d ago
05:36 AM EDT, 09/15/2026 (MT Newswires) -- ImmuPharma (IMM.L) said Tuesday it filed an international Patent Cooperation Treaty application for P140, a peptide-based therapy for autoimmune diseases. The application also covers P140's use in the identification and treatment of patients with the Type M immune profile. The British specialist drug discovery company filed a UK priority patent application for the platform in August 2025. The international patent application incorporates the additional data generated in the last 12 months. ImmuPharma said it is in talks with potential partners for P140 and expects to close a commercial deal in 2026.